Arkolith/Insider Trading/EW/Form 4

Lippis Daniel J.

CVP, TAVREdwards Lifesciences Corp (EW) · full profile →Form 4 · filed May 18, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$50K
Net Open-Market Flow
-$50K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 18, 2026Option exercise(M)620$72.68$45K41K
May 18, 2026Sell(S)620$81.14$50K40K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 18, 2026Option exercise(M)620—$06K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001225208-26-005464) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML